Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078350576> ?p ?o ?g. }
- W2078350576 endingPage "299" @default.
- W2078350576 startingPage "299" @default.
- W2078350576 abstract "Gaucher disease: clinical profile and therapeutic developments Timothy M CoxDepartment of Medicine, University of Cambridge, Cambridge, UKAbstract: Gaucher disease is a rare inborn error of glycosphingolipid metabolism due to deficiency of lysosomal acid β-glucocerebrosidase; the condition has totemic significance for the development of orphan drugs. A designer therapy, which harnesses the mannose receptor to complement the functional defect in macrophages, ameliorates the principal clinical manifestations in hematopoietic bone marrow and viscera. While several aspects of Gaucher disease (particularly those affecting the skeleton and brain) are refractory to treatment, enzyme (replacement) therapy has become a pharmaceutical blockbuster. Human β-glucocerebrosidase was originally obtained from placenta and the Genzyme Corporation (Allston, MA) subsequently developed a recombinant product. After purification, the enzyme is modified to reveal terminal mannose residues which facilitate selective uptake of the protein, imiglucerase (Cerezyme®), in macrophage-rich tissues. The unprecedented success of Cerezyme has attracted fierce competition: two biosimilar agents, velaglucerase-alfa, VPRIV® (Shire Human Genetic Therapies, Dublin, Ireland) and taliglucerase-alfa (Protalix, Carmiel, Israel), are now approved or in late-phase clinical development as potential 'niche busters'. Oral treatments have advantages over biological agents for disorders requiring lifelong therapy and additional stratagems which utilize small, orally active molecules have been introduced; these include two chemically distinct compounds which inhibit uridine diphosphate glucose: N-acylsphingosine glucosyltransferase, the first step in the biosynthesis of glucosylceramide – a key molecular target in Gaucher disease and other glycosphingolipidoses. Academic and commercial enterprises in biotechnology have combined strategically to expand the therapeutic repertoire in Gaucher disease. The innovative potential of orphan drug legislation has been realized – with prodigious rewards for companies embracing its humanitarian precepts. In the era before enzyme therapy, bone marrow transplantation was shown to correct systemic disease in Gaucher patients by supplying a source of competent donor macrophages. As a radical advance on cell- or protein-replacement techniques, contemporary methods for transferring genes to autologous hematopoietic stem cells, and to the brain, merit further exploration. At present, the inflated pharmaceutical niche of Gaucher disease appears to be resilient, but if the remaining unmet needs of patients are to be convincingly addressed and commercial development sustained, courageous scientific investment and clinical experimentation will be needed.Keywords: Gaucher disease, orphan diseases, lysosome, macrophage, enzyme therapy, substrate inhibitors, enzyme replacement" @default.
- W2078350576 created "2016-06-24" @default.
- W2078350576 creator A5080995646 @default.
- W2078350576 date "2010-12-01" @default.
- W2078350576 modified "2023-10-16" @default.
- W2078350576 title "Gaucher disease: clinical profile and therapeutic developments" @default.
- W2078350576 cites W1485152739 @default.
- W2078350576 cites W1487712681 @default.
- W2078350576 cites W1500181036 @default.
- W2078350576 cites W1517097867 @default.
- W2078350576 cites W166253400 @default.
- W2078350576 cites W1831130622 @default.
- W2078350576 cites W1965831290 @default.
- W2078350576 cites W1966180185 @default.
- W2078350576 cites W1968758382 @default.
- W2078350576 cites W1972261063 @default.
- W2078350576 cites W1978105709 @default.
- W2078350576 cites W1981725999 @default.
- W2078350576 cites W1982869943 @default.
- W2078350576 cites W1984531810 @default.
- W2078350576 cites W1985433665 @default.
- W2078350576 cites W1988193452 @default.
- W2078350576 cites W1988253322 @default.
- W2078350576 cites W1991078747 @default.
- W2078350576 cites W1991435307 @default.
- W2078350576 cites W1997261294 @default.
- W2078350576 cites W1999909698 @default.
- W2078350576 cites W2000046902 @default.
- W2078350576 cites W2001910743 @default.
- W2078350576 cites W2007763390 @default.
- W2078350576 cites W2011280194 @default.
- W2078350576 cites W2016845221 @default.
- W2078350576 cites W2017903224 @default.
- W2078350576 cites W2020887709 @default.
- W2078350576 cites W2027459860 @default.
- W2078350576 cites W2032826794 @default.
- W2078350576 cites W2047164992 @default.
- W2078350576 cites W2050889215 @default.
- W2078350576 cites W2053490488 @default.
- W2078350576 cites W2053910695 @default.
- W2078350576 cites W2054646490 @default.
- W2078350576 cites W2055445325 @default.
- W2078350576 cites W2061761213 @default.
- W2078350576 cites W2064430381 @default.
- W2078350576 cites W2067723689 @default.
- W2078350576 cites W2068081016 @default.
- W2078350576 cites W2076107153 @default.
- W2078350576 cites W2076311962 @default.
- W2078350576 cites W2076585244 @default.
- W2078350576 cites W2076780197 @default.
- W2078350576 cites W2077868231 @default.
- W2078350576 cites W2078379563 @default.
- W2078350576 cites W2078624247 @default.
- W2078350576 cites W2079133058 @default.
- W2078350576 cites W2085316805 @default.
- W2078350576 cites W2088638526 @default.
- W2078350576 cites W2093722439 @default.
- W2078350576 cites W2094760955 @default.
- W2078350576 cites W2096739914 @default.
- W2078350576 cites W2101828749 @default.
- W2078350576 cites W2102462689 @default.
- W2078350576 cites W2103986567 @default.
- W2078350576 cites W2104395201 @default.
- W2078350576 cites W2104607370 @default.
- W2078350576 cites W2115381281 @default.
- W2078350576 cites W2116313758 @default.
- W2078350576 cites W2116844182 @default.
- W2078350576 cites W2124663723 @default.
- W2078350576 cites W2125281037 @default.
- W2078350576 cites W2132911597 @default.
- W2078350576 cites W2135424735 @default.
- W2078350576 cites W2141570423 @default.
- W2078350576 cites W2143447170 @default.
- W2078350576 cites W2151743213 @default.
- W2078350576 cites W2157900484 @default.
- W2078350576 cites W2162562000 @default.
- W2078350576 cites W2165524553 @default.
- W2078350576 cites W2166859453 @default.
- W2078350576 cites W2168360177 @default.
- W2078350576 cites W2169237458 @default.
- W2078350576 cites W2187061108 @default.
- W2078350576 cites W2322128806 @default.
- W2078350576 cites W2325709219 @default.
- W2078350576 cites W8192888 @default.
- W2078350576 cites W1922326408 @default.
- W2078350576 cites W2096572725 @default.
- W2078350576 doi "https://doi.org/10.2147/btt.s7582" @default.
- W2078350576 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3010821" @default.
- W2078350576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21209725" @default.
- W2078350576 hasPublicationYear "2010" @default.
- W2078350576 type Work @default.
- W2078350576 sameAs 2078350576 @default.
- W2078350576 citedByCount "56" @default.
- W2078350576 countsByYear W20783505762012 @default.
- W2078350576 countsByYear W20783505762013 @default.
- W2078350576 countsByYear W20783505762014 @default.
- W2078350576 countsByYear W20783505762015 @default.
- W2078350576 countsByYear W20783505762016 @default.